PPW
ALNY icon

Parcion Private Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Parcion Private Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,002
Closed -$398K – 442
2025
Q4 		$398K Buy
1,002
+213
+27% +$94.3K 0.02% 270
2025
Q3 		$360K Buy
+789
New +$321K 0.02% 244
2025
Q2 		– Sell
-748
Closed -$202K – 300
2025
Q1 		$202K Buy
+748
New +$192K 0.02% 274

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parcion Private Wealth's ALNY Position: Q1 2026 in Review

Parcion Private Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,002 shares — an estimated $398K sold.

Parcion Private Wealth first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $398K in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Parcion Private Wealth reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Parcion Private Wealth sold 1,002 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $398K.
  • Parcion Private Wealth first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Parcion Private Wealth's Alnylam Pharmaceuticals position peaked at $398K in Q4 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Parcion Private Wealth's 13F filing for Q1 2026, filed 22 Apr 2026.